PressRelease
HemoVoid™Advances Study of Dried Blood Spot Proteomics
MONMOUTHJUNCTION, NJ, November 26, 2025– Aposter presented at the 2025 Human Proteome (HUPO) World Congress,highlights the advantage of HemoVoid™enrichment in proteomic study of dried blood cards. The poster waspresented by researchers from the Centre for Proteome Research atUniversity of Liverpool and entitled “HAEMOGLOBININTERFERENCE IN DRIED BLOOD SPOT PROTEOMICS FOR 
CHRONIC KIDNEYDISEASE”.
Theuse of dried blood spots is an exciting prospect for longitudinal andat home sampling of pediatric kidney patients. Proteomics allowscharacterization of the blood proteome using liquid chromatography -mass spectrometry (LC-MS). However, the presence of high abundanceproteins, such as hemoglobin, can mask low abundance proteins makingbiomarker discovery less likely. By establishing methods to eliminatehemoglobin from reconstituted dried blood spots, other key proteinscan be identified in Chronic Kidney Disease (CKD) patients.
Theposter states “Comparison of three haemoglobin depletion kits(Biotech Support Group), along with Top 14 (ThermoFisher), found thatHemoVoid removed the highest proportion of haemoglobin (75.79% ±7.9%), with the lowest level of variation, resulting in the highestnumber of identified proteins (545 ± 5).” Furthermore, this methodwas applied to dried blood spots from Stage V CKD patients ondialysis for proof of principle, 136 proteins were identified asbeing statistically different compared to the healthy controls. TheHemoVoid™ workflow allowed for the identification of potentialclinically relevant biomarkers in CKD patients receivinghaemodialysis, using a starting volume of just 10 µL of blood, andavoiding additional venepuncture.
“Weenvision that dried blood cards will become a more prominent sampletype for proteomic investigations, so it is very rewarding to readthis poster as it is a great example of how bead-based enrichment,rather than top-14 depletion, can be so advantageous. The HemoVoid™product used in this study is one of many beads derived from ourunique NRicher™ surface chemistry platform. Not only did HemoVoid™enrichment prove to increase coverage, but it also was able todifferentiate a panel of proteins, some of which may becomeproductive biomarkers. stated Dr. Swapan Roy, President and Founderof Biotech Support Group.
Formore information on HemoVoid™, visit:
http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm
Formore information of all of our Hemoglobin removal products, visit:
https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm
Formore information on our NRicher™ bead chemistry platform, visit:
https://www.biotechsupportgroup.com/category-s/340.htm
AboutBiotech Support Group LLC
BiotechSupport Group develops innovative sample preparation technologiesthat address the emerging needs of proteomics, biomarker discovery,and personalized medicine. Flagship products include Cleanascite™for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum proteindepletion, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NRicher™ for low abundance, family specific, and targetedproteome enrichment.These products support translational research by simplifyingworkflows and improving sample quality for downstream analysis.
ForBusiness Development Inquiries:
Matthew Kuruc
Phone:732-274-2866
Email: [email protected]
Keywords:HemoVoid™, Hemoglobin depletion, Hemoglobin removal, chronic kidneydisease (CKD), dried blood spot proteomics